RXRX

Avoid

Recursion Pharmaceuticals

NASDAQ · US AI Pure Play 🇺🇸

22.73

Dorlexa Score™

Confidence: 62%

Score Breakdown

AI Leverage5.8 / 12

AI revenue exposure, R&D intensity, and strategic AI positioning

Weight: 12%

Growth Quality3.3 / 15

Revenue growth trajectory, margin expansion, and ROE quality

Weight: 15%

Profitability3.5 / 15

Gross margin, operating margin, and free cash flow quality

Weight: 15%

Competitive Moat7.4 / 20

Market leadership, scale advantages, R&D depth, and ROE durability

Weight: 20%

Valuation0.0 / 8

EV/Sales, PEG ratio, and discount from 52-week high

Weight: 8%

Momentum & Trend5.6 / 30

12-month price momentum, 3-month acceleration, trend regime, and volatility

Weight: 30%

Last scored: Mar 22, 2026 · Model: stock_v4.0